Source: Getty Images Avelumab plus axitinib was associated with signifi­cantly longer progression-free survival than ...

The study added to a limited database about the effects of perioperative IO combinations, which have emerged as standard of ...

LOUISVILLE, Ky. -- More than half of patients with newly diagnosed metastatic kidney cancer responded to a novel drug ...

Get detailed information on Ipilimumab, including pronunciation, uses, dosage guidelines, indications, and instructions on how and when to take it and when to avoid it. The updated prescription ...

Previous systemic therapies received, including adjuvant treatment, are listed in the Data Supplement (Table S2). Fig 1. Patient flow. IPI, ipilimumab; NIVO, nivolumab. Median follow-up for OS was ...

Patients with dMMR colon cancer in a trial for two neoadjuvant cycles of nivolumab/ipilimumab or nivolumab/relatlimab, had ...

The following is a summary of “Pooled Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone in Patients With Advanced Melanoma,” published in the November 2024 issue of Oncology by Long ...

Patients with MSI-high/dMMR advanced colorectal cancers had a 79 percent lower risk of disease progression or death on Opdivo-Yervoy compared to chemo.

周四，H.C. Wainwright调整了对Genelux Corp. (NASDAQ:GNLX)股票的财务展望，将目标价从32美元下调至30美元，同时维持对该股的买入评级。这一调整是在Genelux周三收市后发布2024年第三季度财报和公司更新之后做出的。 报告强调了Genelux与中国Newsoara Biopharma的持续合作，指出复发性小细胞肺癌(SCLC)的1b/2期临床试验患者招募和 ...

Sienna Senior Living Inc. ("Sienna" or the "Company") today announced a dividend of $0.078 per common share of the Company (each, a "Common Share") for the month of November 2024, representing $0.936 ...

An experimental new cancer drug has proven beneficial for a handful of individuals. If all goes to plan, it will be available ...